Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, AYTU BIOPHARMA, INC reported revenue of $66M, up 1.8% year over year. Operating margin was -11.8% and net margin -20.4%, on a free-cash-flow margin of -3.3% with capital expenditure at 0.3% of revenue. Every figure is computed directly from AYTU's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $66M | -11.8% | -20.4% |
| FY2024 | $65M | -2.4% | -24.3% |
| FY2023 | $107M | -15.9% | -15.9% |
| FY2022 | $97M | -113.7% | -112.5% |
| FY2021 | $66M | -89.7% | -88.8% |
How does AYTU compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.